Special Issue "Extracellular Vesicles in Cancer Progression and Drug Resistance"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 October 2019

Special Issue Editor

Guest Editor
Prof. Dr. M. Helena Vasconcelos

1. FFUP – Faculdade de Farmácia da Universidade do Porto, Porto 4050-313, Potugal
2. i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto 4200-135, Portugal
Website 1 | Website 2 | E-Mail
Interests: cancer drug resistance; cancer multidrug resistance; intercellular transfer of drug resistance mediated by extracellular vesicles (EVs); new approaches to overcome drug resistance; drug-efflux pumps; escape from apoptosis; autophagy; metabolic alterations associated with drug resistance; tumour–microenvironment interactions; cancer stem cells; microRNAs; biomarkers of minimal residual disease; biomarkers of drug resistance

Special Issue Information

Dear Colleagues,

The release of extracellular vesicles (EVs) by cancer cells has tremendous impact in cancer progression, from the proliferation of cancer cells to ECM degradation, angiogenesis, metastasis, escape from immune response, or drug resistance. This is as a result of the horizontal transfer of the EV’s cargo (such as proteins, miRNAs, or long noncoding RNAs) from the donor cells to recipient cells. EVs are also responsible for drug efflux from the donor cells, reducing the intracellular drug concentrations to sublethal ones.

Remarkably, the presence of EVs released by tumour cells in the biological fluids of cancer patients is allowing their study as a possible source of biomarkers in liquid biopsies, for diagnosis or prognosis purposes.

This Special Issue of Cancers aims to collect review and original research articles on the impact of EVs on cancer progression and drug resistance, and also on cancer patient’s diagnosis and prognosis. Topics may include, but are not exclusively limited to, studying the following: (i) role of EVs in the various hallmarks of cancer; (ii) cargo of EVs and their horizontal transfer; (iii) mechanisms of release of EVs by donor cells, and their uptake by recipient cells; (iv) search for biomarkers of cancer diagnosis or prognosis in liquid biopsies.

Prof. Dr. M. Helena Vasconcelos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Extracellular vesicles
  • Cancer progression
  • Hallmarks of cancer
  • Cancer drug resistance
  • Biomarkers of cancer diagnosis
  • Biomarkers of cancer prognosis
  • Biomarkers of minimal residual disease
  • Liquid biopsies

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top